After a kick-start from Bill Gates, a Silicon Valley company aims to be the 'Intel Inside' of the $200 billion sweetener and skincare market

After a kick-start from Bill Gates, a Silicon Valley company aims to be the 'Intel Inside' of the $200 billion sweetener and skincare market

skin serum


Synthetic biology company Amyris is charging into health with a focus on fragrances, skincare, and sweetener.

  • Bay Area synthetic biology company Amyris tried to transform the transportation industry with sustainably-produced fuel, but the effort flopped.
  • Now, it's charging into health with a focus on fragrances, skincare, and sweetener.
  • Amyris uses living organisms instead of traditional manufacturing processes to make its ingredients faster, cheaper, and with less of an impact on the environment.
  • Business Insider recently toured the company's 600-person Emeryville, Calif. facility and tried two of its new products: a zero-calorie sweetener and a line of face creams which can be found at Sephora.

After a valiant-but-failed attempt at disrupting the oil industry with microorganisms that churned out clean fuel, Amyris is charging into the consumer health arena.

The Bay Area company, which went public in 2010 after spending seven years as a startup, is still driven by the same renewable principles that inspired its biofuels push. This time, they're being applied to products like fragrances, skincare, and sweetener.

Amyris is a pioneer in the field of synthetic biology. The goal is to move away from old, highly polluting manufacturing processes based on petrochemicals to cheaper, faster, and more sustainable methods founded on cells. Essentially, Amyris uses living things to manufacture its ingredients.

Synthetic biology has been a struggle financially. Amyris has reported financial losses every year but one since its 2010 IPO, and the company's stock has lost nearly 99% over that time period. Today, the shares are trading at roughly $3, giving the company a market value of about $250 million.


Still, a growing group of companies are pursuing similar techniques to make less-toxic sweeteners for food, biodegradable building materials, and foldable electronics, and investors have been pouring money into the field. From 2012 to 2017, funding for synthetic biology startups more than tripled, surpassing the $1 billion mark in 2016, according to a report from CB Insights.

Earlier this month, a synthetic biology startup called Zymergen raised $400 million from investors including SoftBank and Goldman Sachs. Its aim is to make novel items like ultra-durable coatings and nontoxic insect repellents. (Of Zymergen's three co-founders, two came from Amyris.)

Amyris is taking a different tack. It's focused on making superior versions of consumer products that already exist. That includes perfumes, moisturizers, and sweeteners that are cheaper, can be made faster, and are less environmentally-damaging than what most people use today.

"I want people to become aware of us because we're in their lives," Amyris CEO John Melo told Business Insider on a recent tour of the company's Emeryville, California headquarters, just north of Oakland.

"If I were to extrapolate that to its fullest, I would love to be the 'Intel Inside' everybody's goods."


Read more: A Silicon Valley startup with 26 patents under its belt just raised $400 million from SoftBank and Goldman Sachs to make materials from living things

Inside Amyris' plan for global domination

amyris emeryville Lab 5

Courtesy Amyris

Billionaire philanthropist Bill Gates is responsible for much of Amyris' present renown.

Inside Amyris' sprawling, multistory headquarters in a rapidly developing part of Emeryville, the sound of humming robots and other pricey lab equipment fills the air. Hundreds of employees work with the glimmering equipment to churn out all of the base ingredients for its range of consumer products.

A decade ago, a much smaller set of machinery was being used to make industrial goods. With funds from investors including Khosla Ventures and Kleiner Perkins and support from billionaire Bill Gates, Amyris produced the precursors to malaria drugs and hydrocarbon-based biofuel.

But neither operation could compete financially with traditional manufacturing processes, so after years of work, Amyris had to either shut down or spin off both enterprises.


Read more: 40 AND UNDER: The Silicon Valley biotech stars who are backing startups aiming to cure disease, prolong life, and fix the food system

Still, Melo doesn't think the company's work on malaria or fuel was all for nothing. Today, he says the work on consumer goods is succeeding - largely thanks to the hard lessons learned in biofuels.

"Not everybody has the benefit of those pieces," Melo said.

From malaria drugs to biofuels to skincare, fragrances, and sweetener

amyris biossance skincare sephora

Courtesy Amyris

Amyris' Biossance products, sold at Sephora, contain up to 60% of the skin-quenching ingredient squalene. Only theirs is made with microbes, not shark livers.

Luckily for a company like Amyris, shifting from one industry to another isn't as difficult as it sounds.

"Instead of a chemical company which has to change the pipes, all we have to do is change the organism," Joel Cherry, Amyris' president of research and development, said in December.


And changing the organism is precisely what Amyris did when it entered the health space in 2016.

Instead of focusing exclusively on yeast, the company feeds the same sugarcane waste that it used for malaria treatments and biofuel to a host of microorganisms like E. coli and different kinds of fungus.

The company can coax the microbes into making the scent of patchouli or sandalwood for Chanel perfume, or the moisturizing emollient in its own lineup of skincare products called Biossance, which have been sold at big name retailers like Sephora since 2017. Together, the sweetener and skincare industries provide Amyris with $200 billion in market potential, Melo estimated.

And to ensure that it can compete financially, Amyris specifically looks for products whose supply could be threatened by changing climates or irregular harvests.

Read more: A controversial technology could save us from starvation - if we let it


In its Biossance products, the key ingredient that Amyris makes is called squalene. Normally derived from shark livers, the ingredient is prized by the cosmetic industry for its ability to hold moisture and keep skin soft and pliable. But dozens of countries have banned shark hunting, which harms the species along with the ocean ecosystems. So Amyris makes squalene with genetically engineered microbes instead.

Amyris' unique production method for squalene has other benefits, too.

John Melo Headshot amyris ceo

Courtesy Amyris

Amyris CEO John Melo

In most face and body products, squalene only exists as a tiny fraction (some 2-10%) of the overall ingredient list. But some of Amyris' Biossance products contain as much as 60% of the prized ingredient, something Melo says they do simply because they can.

"That's the strategy for everything we do, where people start with a small volume of our ingredient because they can claim it, it's good, and it does good things for the final product," Melo said. "The more they use it, the more they decide, 'We should be using more of this.'"

The company hopes to do the same thing with its new zero-calorie sweetener, made using synthetic biology and an ingredient from the stevia plant.


Read more: There's growing evidence that eating fat won't make you fat, but sugar will

In October, Amyris signed its first major supply and distribution agreement with ASR Group, the largest cane sugar refiner in the world. Last month, protein shake company Shaklee announced it would make its shakes with Amyris' sweetener.

amyris chocolate

Erin Brodwin / Business Insider

Business Insider sampled coffee sweetened with a packet of the ingredient and tasted a chocolate bar made with the product. Both tasted similar to products sweetened with Splenda (sucralose) or Stevia, only without the bitter aftertaste.

"We go after big problems and part of that is going after markets where we can be the number one technology in the world for those markets," Melo said.


"I think of sweetener as the next market that we're entering, and there will be many more."

Business Insider Intelligence Exclusive FREE Report: The 5 Ways AI Will Change U.S. Healthcare